[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Caris Life Sciences Inc (CAI)

Caris Life Sciences Inc (CAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,505,935
  • Shares Outstanding, K 282,681
  • Annual Sales, $ 812,030 K
  • Annual Income, $ -68,090 K
  • EBIT $ 108 M
  • EBITDA $ 144 M
  • 60-Month Beta N/A
  • Price/Sales 5.47
  • Price/Cash Flow 9.85
  • Price/Book 7.48

Options Overview Details

View History
  • Implied Volatility 76.82% (+4.34%)
  • Historical Volatility 90.01%
  • IV Percentile 29%
  • IV Rank 29.34%
  • IV High 132.24% on 03/18/26
  • IV Low 53.81% on 01/21/26
  • Expected Move (DTE 27) 2.21 (14.21%)
  • Put/Call Vol Ratio 0.46
  • Today's Volume 280
  • Volume Avg (30-Day) 262
  • Put/Call OI Ratio 0.99
  • Today's Open Interest 7,623
  • Open Int (30-Day) 6,765
  • Expected Range 13.34 to 17.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.01
  • Number of Estimates 4
  • High Estimate $0.02
  • Low Estimate $0.00
  • Prior Year $-0.54
  • Growth Rate Est. (year over year) +101.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.19 +9.58%
on 05/13/26
20.73 -24.99%
on 04/27/26
-4.95 (-24.15%)
since 04/22/26
3-Month
14.19 +9.58%
on 05/13/26
22.16 -29.83%
on 04/21/26
-3.98 (-20.38%)
since 02/20/26

Most Recent Stories

More News
You’ve Likely Never Heard of Caris Life Sciences Stock. Billionaire Stanley Druckenmiller Has – and He Likes What He Sees.

Caris Life Sciences just earned a $33.87 million vote of confidence from Stanley Druckenmiller, and most people completely missed it.

CAI : 15.55 (-2.45%)
Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek

The Caris Lookback Program identified 13,293 patients potentially eligible for newly approved targeted therapies across 10 tumor types

CAI : 15.55 (-2.45%)
Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%

Caris Life Sciences (NASDAQ:CAI) executives said the company is expanding its commercial reach, product pipeline and biopharma partnerships as it looks to build on recent revenue growth following its IPO...

CAI : 15.55 (-2.45%)
Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels

Targeted gene panels miscalculate tumor mutational burden in 10–15% of patients, directly resulting in incorrect pembrolizumab eligibility determination

CAI : 15.55 (-2.45%)
Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood‑Based Testing Authorization

IRVING, Texas , May 8, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced...

CAI : 15.55 (-2.45%)
Caris Life Sciences Q1 Earnings Call Highlights

Caris Life Sciences (NASDAQ:CAI) reported first-quarter 2026 results highlighted by sharp year-over-year revenue growth, improving margins, and continued progress across its pipeline, including a key clinical...

CAI : 15.55 (-2.45%)
Caris Life Sciences Reports First Quarter 2026 Financial Results

Revenue growth of 79% driven by strong performance in molecular profiling services

CAI : 15.55 (-2.45%)
Caris Life Sciences Reports Tomorrow but Reimbursement Reality May Finally Catch Up

Barchart Research What to Expect from CAI Earnings CAI Generated May 6, 2026 Current Price $19.13 EPS Estimate $$-0.02 Consensus Rating Strong Buy Average Move 8.68% Caris Life Sciences Reports Tomorrow...

CAI : 15.55 (-2.45%)
Caris Life Sciences Launches Caris MI Clarity, the First and Only AI-Powered Test to Predict Both Early and Late Distant Recurrence Risk in Breast Cancer at the Time of Diagnosis

Caris MI Clarity leverages AI to transform how recurrence risk is understood and applied in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer

CAI : 15.55 (-2.45%)
Caris Life Sciences Receives MolDX Approval for Caris ChromoSeq, Advancing Access to Comprehensive Genomic Profiling for Myeloid Malignancies

IRVING, Texas , May 4, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient‑centric, next‑generation AI TechBio company and precision medicine pioneer, today announced...

CAI : 15.55 (-2.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Caris Life Sciences Inc. provides diagnostics and anatomic pathology services. It develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring and precision medicine enabling aspects. Caris Life Sciences Inc. is based in Irving,...

See More

Key Turning Points

3rd Resistance Point 16.90
2nd Resistance Point 16.62
1st Resistance Point 16.08
Last Price 15.55
1st Support Level 15.26
2nd Support Level 14.98
3rd Support Level 14.44

See More

52-Week High 42.50
Fibonacci 61.8% 31.69
Fibonacci 50% 28.34
Fibonacci 38.2% 25.00
Last Price 15.55
52-Week Low 14.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.